Adaptive Biotechnologies (ADPT) Change in Receivables (2018 - 2026)

Adaptive Biotechnologies has disclosed Change in Receivables across 9 years of filings, most recently posting $1.2 million for Q2 2026.

• In Q2 2026, Change in Receivables rose 70.66% year-over-year to $1.2 million; the TTM figure through Jun 2026 stood at $5.2 million (down 39.69% YoY), while the FY2025 annual figure was $8.6 million, up 130.93% from the prior year.
• Change in Receivables came in at $1.2 million for Q2 2026 at Adaptive Biotechnologies, up from -$2.0 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $13.5 million in Q4 2022 to a low of -$9.1 million in Q1 2023.
• Average Change in Receivables over 5 years is $1.8 million, with a median of $1.2 million recorded in 2022.
• Year-over-year, Change in Receivables surged 4606.97% in 2022 and sank 1132.37% in 2024.
• Over 5 years, Change in Receivables stood at $13.5 million in 2022, then plunged by 49.91% to $6.8 million in 2023, then sank by 86.71% to $899000.0 in 2024, then jumped by 516.69% to $5.5 million in 2025, then plunged by 78.39% to $1.2 million in 2026.
• Per Business Quant data, the three most recent Change in Receivables figures were $1.2 million in Q2 2026, -$2.0 million in Q1 2026, and $5.5 million in Q4 2025.